Zoetis Inc. (ZTS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $69.69. The rating moved from Neutral to Oversold on October 3, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$69.69
• Last changeMoved from Neutral to Oversold on October 3, 2026
• SectorHealthcare
• IndustryDrug Manufacturers - Specialty & Generic

See all oversold Healthcare stocks →

AI analysis

Zoetis Inc. (ZTS) has a durable, high-margin business across companion and production animal health with steady cash generation and a pipeline supplemented by targeted M&A. The company’s defensive demand profile and global diversification support near-term resilience, while growth is balanced by livestock cyclicality, regulatory scrutiny on veterinary drugs, and channel/pricing pressures. Insider buying and the product cadence provide upside catalysts, but supply-chain or macro shocks could weigh on results.

Key factors

• Market leader in animal health with leading franchises across companion animals and livestock, supporting stable market share
• Recurring, high-margin revenue mix (vaccines, parasiticides, biologics) that supports strong free cash flow and returns to shareholders
• Diversified global footprint reduces dependence on any single market and provides growth optionality in emerging markets
• Defensive demand characteristics for companion-animal care, which can outperform in risk-off environments
• Active R&D and disciplined M&A history that replenish product pipeline and drive incremental growth
• Recent insider Form 4 activity signals management confidence in the business

Risks

• Livestock demand cyclicality and agricultural commodity pressure that can compress volumes and pricing in the large-animal segment
• Regulatory and public-policy risk (e.g., restrictions on antimicrobials, import/export rules) that could limit product usage or increase compliance costs
• Pricing pressure from consolidated distributors, large buyers and channel shifts (online retail, corporate vet chains) that could erode margins
• Supply-chain disruptions or manufacturing constraints that impact product availability and near-term revenue
• Currency exposure and geopolitical volatility that can affect international sales and reported results
• Broader macro risk and investor risk-off sentiment that may compress multiples despite steady fundamentals

Latest MarketMoodz coverage

• Texas Screwworm Case Lifts Zoetis, Sparks Options Surge2026-06-04
• Burry Buys Beaten Stocks, Warns of AI-Fueled Dot-Com Echo2026-05-19
• Cisco Hits RSI 90 — Most Overbought S&P 500 Stock2026-05-16

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.